0001104659-24-009543.txt : 20240201
0001104659-24-009543.hdr.sgml : 20240201
20240201180325
ACCESSION NUMBER: 0001104659-24-009543
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240130
FILED AS OF DATE: 20240201
DATE AS OF CHANGE: 20240201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roberts M Scot
CENTRAL INDEX KEY: 0001705905
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32587
FILM NUMBER: 24588163
MAIL ADDRESS:
STREET 1: 910 CLOPPER ROAD, SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Altimmune, Inc.
CENTRAL INDEX KEY: 0001326190
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 202726770
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 2406541450
MAIL ADDRESS:
STREET 1: 910 CLOPPER ROAD
STREET 2: SUITE 201S
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: PHARMATHENE, INC
DATE OF NAME CHANGE: 20071016
FORMER COMPANY:
FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP
DATE OF NAME CHANGE: 20050505
4
1
tm244961-5_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-30
0
0001326190
Altimmune, Inc.
ALT
0001705905
Roberts M Scot
C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,
SUITE 201S
GAITHERSBURG
MD
20878
0
1
0
0
Chief Scientific Officer
0
Common Stock, par value $0.0001
2024-01-30
4
M
0
9275
0
A
29699
D
Common Stock, par value $0.0001
2024-01-30
4
F
0
2709
9.80
D
26990
D
Common Stock, par value $0.0001
2024-01-31
4
A
0
5860
2.69
A
32850
D
Common Stock, par value $0.0001
15
I
Shares held by spouse of Reporting Person
Restricted Stock Units
2024-01-30
4
M
0
9275
0.00
D
Common Stock, par value $0.0001
9275
27825
D
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024.
In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023.
The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
/s/ Richard I. Eisenstadt, as Attorney-in-Fact
2024-02-01